Ambassade des Etats-Unis en Djibouti

The U.S. Embassy in Djibouti announces a new donation by the U.S. Government of 29,250 doses of Pfizer’s COVID-19 vaccine as part of the U.S. Administration’s global efforts to fight the COVID-19 pandemic. The vaccines arrived in Djibouti on Saturday, January 1st and were transferred to the Military Hospital of Djibouti where they are safely stored at -80 degrees Celsius.

This donation, coordinated by COVAX, will help protect the population of Djibouti, including persons under the age of 18, from the COVID-19 virus and prevent the further spread of the virus’ new strains. The U.S. Government fully supports the Djiboutian authorities’ vaccination efforts and encourages everyone to get vaccinated.

U.S. Embassy Deputy Chief of Mission Andrea Tomaszewicz and USAID Acting Country Representative Martha Dye toured the hospital storage facility today along with representatives from UNICEF and Dr. Omar Mahamoud Ismael, the Coordinator of the Ministry of Health’s Vaccine Program. DCM Tomaszewicz emphasized the United States’ longstanding commitment to ensuring access to health services for the people of Djibouti, and how this assistance is even more important now as we all face the challenges of the new variants of COVID-19 together.

The donation of the Pfizer vaccine, along with the Johnson and Johnson vaccines donated by the U.S. in July of last year, provides another example of how the partnership between the U.S. and Djibouti is working to benefit all Djiboutians.

Distributed by APO Group on behalf of Ambassade des Etats-Unis en Djibouti.

Send us your press releases to

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.